Src inhibitor
Src inhibitor is a class of inhibitors that targets src kinase family, which is transcribed by proto-oncogenes src genes (abbreviating for sarcome genes) that potentially induced cell of malignant transformation. Because of the crucial position of src gene/kinase in cells, src inhibitors may have prospect to be antineoplastic agents used for pancreatic cancer, breast cancer, stomach cancer et al.
chemical structure of KX2-391
Examples
- KX2-391 is an oral src inhibitor and the first clinical inhibitor with GI50 of 9–60 nM in cancer cell lines.[1]
- Bosutinib has been developed for the treatment of chronic myelogenous leukemia by Pfizer.
- Saracatinib, the first Src inhibitor to show inhibition of the Src pathway in human tumor tissue, has anti-tumor activity alone or in combination with chemotherapeutic agents.[2]
chemical structure of PP1
References
- ↑ Antonarakis ES, Heath EI, Posadas EM, Yu EY, et al. (Apr 2013). "A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.". Cancer Chemother Pharmacol. 71 (4): 883–892. doi:10.1007/s00280-013-2079-z. PMID 23314737.
- ↑ Nam HJ, et al. "Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.". Mol Cancer Ther. 12 (1): 16–26. doi:10.1158/1535-7163.MCT-12-0109. PMID 23144237.
- ↑ "PP1 is a potent and selective Src inhibitor for Lck/Fyn".
- ↑ "biological activity of PP2 in selleck chemicals". Selleck Texas.
This article is issued from Wikipedia - version of the 8/13/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.